10% Curcuma xanthorriza cream for treating melasma
Effectiveness of Curcuma Xanthorriza Roxb. 10% Cream in Reducing Melasma Area and Severity Index (MASI) Scores and Improvement of Skin Brightness in Epidermal Type Melasma
This study is testing a 10% cream made from Curcuma xanthorriza to see if it can help people with melasma by comparing it to a 2% Kojic Acid treatment.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Sex | All |
| Sponsor | Universitas Padjadjaran Academic / other |
| Locations | 1 site (Bandung, West Java) |
| Trial ID | NCT06153134 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the efficacy of a 10% cream made from Curcuma xanthorriza Roxb. as a treatment for melasma, a skin condition characterized by hyperpigmentation. The study employs a split-face therapy approach, comparing the effects of the Curcuma cream against a 2% Kojic Acid treatment. Participants will be assessed using MASI scores and spectrophotometry to evaluate changes in skin brightness and melasma severity. The trial aims to provide an alternative depigmentation agent that may reduce the recurrence and side effects associated with traditional treatments.
Who should consider this trial
Good fit: Ideal candidates include both males and females diagnosed with epidermal-type melasma who have lesions on both sides of their face.
Not a fit: Patients with a history of hypersensitivity to Curcuma xanthorriza or kojic acid, as well as those currently using certain medications or undergoing specific aesthetic procedures, may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a safer and more effective option for patients suffering from melasma.
How similar studies have performed: While there has been research on other Curcuma species, this specific approach using Curcuma xanthorriza Roxb. as a depigmentation agent is novel and has not been previously tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Females and males diagnosed with epidermal-type melasma clinically and through Wood's lamp examination. * Study subjects exhibit melasma lesions on both sides of the face. Exclusion Criteria: * History of hypersensitivity to Curcuma xanthorriza Roxb. or kojic acid based on anamnesis. * Pregnant and breastfeeding women. * Patients using hormonal contraceptive drugs in the last 3 months. * Patients using topical medications (depigmentation agents, tretinoin, or corticosteroids) in the skin area to be tested in the last 2 weeks. * Patients using systemic corticosteroids in the last 1 month. * Patients undergoing laser therapy, microdermabrasion, chemical peels, and other aesthetic procedures in the skin area to be tested in the last 1 month. * Patients experiencing inflammation on the facial skin.
Where this trial is running
Bandung, West Java
- Hasan Sadikin General Hospital — Bandung, West Java, Indonesia (Recruiting)
Study contacts
- Study coordinator: Fathia Rianty, M.D.
- Email: fathrianty@gmail.com
- Phone: +6281225955478
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.